Matthew J LaVoie PhD
- Mailing Address:
-
PO Box 100159
GAINESVILLE FL 32610
- Physical Address:
-
1275 CENTER DR
GAINESVILLE FL 32610
The overall goal of the LaVoie lab is to elucidate the earliest molecular events responsible for adult onset neurodegenerative diseases. We approach these devastating disorders from both the perspective that specific inherited gene mutations linked to familial forms can provide valuable insight, as well as maintaining a focus on aspects of the far more common sporadic forms. The LaVoie lab employs a diverse array of state-of-the-art tools to accomplish these goals including a series of novel knockin animal models, iPSC-based neuronal and glial cultures, and CRISPR/Cas9 genome editing.
Our focus on familial Parkinson’s disease is centered on pathogenic mutations in the Parkin and LRRK2 genes. Parkin is an ubiquitin E3 ligase which is highly expressed in neurons. Autosomal recessive, loss-of-function mutations in the Parkin gene are associated with an often early onset form of Parkinson’s disease. The precise role of parkin within the neuron is not clear, however, data from multiple model organisms strongly support both homeostatic and pro-survival functions of parkin that impact mitochondrial biology. Our ongoing work seeks to understand how a primarily cytosolic protein such as parkin possesses such a potent influence on mitochondria.
LRRK2 is a large multi-domain kinase linked to PD via autosomal dominant inheritance of several mutations that span the entire protein. Given the complex nature of the LRRK2 protein itself, and the fact that PD-linked mutations occur in multiple domains, a primary goal of our work is to understand the physiological function and regulation of wild-type LRRK2. Then, we hope to uncover divergent behaviors and consequences of various PD-linked mutants (e.g. R1441C/G/H, Y1699C, G2019S, I2020T). Our recent work has shown that the highly active LRRK2 dimer resides at the cell membrane, regulates lysosomal function and influences the neuronal metabolism of alpha-synuclein, a protein whose aggregation is believed to drive the pathogenesis in PD. Ongoing work seeks to determine the physiological and pathological implications of this LRRK2 mutation, its role in idiopathic disease, and crosstalk between LRRK2 signaling pathways and other genetic risk factors for PD.
In seeking to understand the pathological consequences of the widely reported mitochondrial Complex-1 dysfunction in sporadic PD, the LaVoie lab utilizes a combination of novel cell culture and animal models deficient in various genes critical to mitochondrial function to examine the primary pathological events that follow mitochondrial disturbance. In addition, we are uncovering novel mechanisms to improve mitochondrial function in the hopes to identify opportunities slow or halt disease progression in patients.
- Alzheimer’s Disease
- Lewy Body Dementia
- Parkinson’s disease
- Progressive Supranuclear Palsy (PSP)
- 2024 Stem cell reports
- 2023 bioRxiv : the preprint server for biology
- 2023 Frontiers in neuroscience
- 2023 Acta neuropathologica communications
- 2023 Acta neuropathologica communications
- 2022 PLoS biology
- 2021 PLoS biology
- 2021 Brain research
- 2021 Brain research
- 2020 Movement disorders : official journal of the Movement Disorder Society
- 2020 Frontiers in neuroscience
- 2020 Neuron
- 2018 Proceedings of the National Academy of Sciences of the United States of America
- 2018 Neurobiology of disease
- 2016 Proceedings of the National Academy of Sciences of the United States of America
- 2016 Autophagy
- 2015 Neuroscience
- 2015 Molecular and cellular neurosciences
- 2015 Annals of neurology
- 2014 The Journal of cell biology
- 2014 Human molecular genetics
- 2014 Cell death & disease
- 2014 American journal of hematology
- 2013 Neurobiology of disease
- 2012 Proceedings of the National Academy of Sciences of the United States of America
- 2012 Cell cycle (Georgetown, Tex.)
- 2011 Cold Spring Harbor perspectives in biology
- 2011 Cell
- 2011 Journal of neural transmission (Vienna, Austria : 1996)
- 2010 Biochemistry
- 2010 The Journal of biological chemistry
- 2009 Human molecular genetics
- 2009 Journal of neurochemistry
- 2009 Human molecular genetics
- 2009 Biochemistry
- 2007 Journal of neurochemistry
- 2005 The Journal of biological chemistry
- 2005 Nature medicine
- 2004 Biochemistry
-
2004
Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity.Experimental neurology
- 2004 Molecular and cellular neurosciences
- 2004 Biochemistry
- 2003 The Journal of biological chemistry
- 2003 Proceedings of the National Academy of Sciences of the United States of America
- 2003 Biochemistry
- 2003 Neurobiology of disease
- 2003 The Journal of biological chemistry
- 2002 The Journal of biological chemistry
- 2000 Nursing ethics
- 1999 Journal of neurochemistry
- 1999 The Journal of neuroscience : the official journal of the Society for Neuroscience
-
Aug 2024
ACTIVE
Interrogating Novel Glycan Defects in GBA1-PDFOX FOU, MICHAEL J · Principal Investigator
-
Jul 2024
ACTIVE
Intersection of GBA and LRRK2 in Lewy Body DementiaNATL INST OF HLTH NIA · Principal Investigator
-
Jul 2023
ACTIVE
Iron homeostasis and inflammatory responses in human LRRK2 astrocytesFOX FOU, MICHAEL J · Co-Project Director/Principal Investigator
-
Dec 2022
ACTIVE
Dysregulation of iron homeostasis by mutant LRRK2 in human neuronsNATL INST OF HLTH NIA · Co-Investigator
-
Sep 2022
ACTIVE
Deciphering tau phosphorylation and Abeta/tau strain interactions in Alzheimers pathogenesisNATL INST OF HLTH NIA · Co-Investigator
-
Jun 2022
ACTIVE
Protection of dopaminergic neuronal functionPARKINSONS FOU · Other
-
Mar 2021
–
Sep 2023
Role of LRRK2 in Gcase-mediated alterations in lysosome function and alpha-synuclein metabolismFOX FOU, MICHAEL J · Principal Investigator
-
Jul 2020
–
Jun 2024
PATHOLOGIC LRRK2 SIGNALING IN FAMILIAL AND IDIOPATHIC PARKINSON'S DISEASENATL INST OF HLTH NINDS · Principal Investigator
-
May 2020
–
May 2022
Role of Parkin in Familial and Idiopathic Parkinson's DiseaseNATL INST OF HLTH NINDS · Principal Investigator
-
2000
PhD in NeuroscienceUniversity of Pittsburgh
-
1995
BA/BS in Biology/PsychologyRutgers College